Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026
Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026
Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026
Company Deals

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Fineline Cube Mar 24, 2026
Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026
Company Drug

Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada

Fineline Cube Mar 25, 2026
Company Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Fineline Cube Mar 25, 2026
Company Drug

CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials

Fineline Cube Aug 24, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...

Policy / Regulatory

China’s Health Commission Promotes Medical-Elderly Care Integration

Fineline Cube Aug 24, 2022

China’s National Health Commission (NHC), National Development and Reform Commission (NDRC), and National Healthcare Security...

Policy / Regulatory

China Passes WHO NRA Evaluation for Vaccine Regulatory System

Fineline Cube Aug 24, 2022

The World Health Organization (WHO) announced that China has successfully passed the evaluation of its...

Company Drug

SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial

Fineline Cube Aug 24, 2022

Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products...

Company Drug

Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...

Company Drug

BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer

Fineline Cube Aug 24, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...

Company Drug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

Fineline Cube Aug 24, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...

Company Deals

Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products

Fineline Cube Aug 24, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...

Company Deals

Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS

Fineline Cube Aug 24, 2022

Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...

Drug Legal / IP

Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case

Fineline Cube Aug 24, 2022

China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...

Company

Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth

Fineline Cube Aug 23, 2022

Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...

Company Drug

Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review

Fineline Cube Aug 23, 2022

The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...

Company Deals

Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19

Fineline Cube Aug 23, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...

Company Drug

Anhui Anke’s HK010 Bispecific Antibody Receives NMPA Review for Cancer Trials

Fineline Cube Aug 23, 2022

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that the National Medical Products Administration...

Company Deals

China-Based Firms Form Partnership to Advance Cell and Gene Therapy Ecosystem

Fineline Cube Aug 23, 2022

Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co.,...

Company Deals

BIOPSEE Series A+ Financing Confocal Microendoscope

Fineline Cube Aug 23, 2022

BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...

Company Drug

CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials

Fineline Cube Aug 23, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer

Fineline Cube Aug 23, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...

Company Drug

Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC

Fineline Cube Aug 23, 2022

Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...

Posts pagination

1 … 607 608 609 … 640

Recent updates

  • Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada
  • Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer
  • WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects
  • Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections
  • Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada

Company Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Company

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Company Drug

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.